The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

January 17, 2018 • By Will Boggs MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials.

You Might Also Like
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
  • Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women
  • Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal

“These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University of California, San Francisco, told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Drugs used to prevent and treat osteoporosis typically cause short-term changes in bone-turnover markers, but few studies have linked these changes to subsequent fracture reduction.

Dr. Bauer and colleagues in the Foundation for the National Institutes of Health (FNIH) Bone Quality Project analyzed individual-level data from 28,000 participants enrolled in 14 fracture-endpoint trials (11 of bisphosphonate and three of selective estrogen receptor modulator) in order to determine whether short-term changes in bone-turnover markers (BTMs) predict fracture outcomes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In general, greater reductions in BTMs with therapy were associated with greater reductions in fracture risk, and the association was more striking for bone-formation markers – bone-specific alkaline phosphatase (bone ALP) and pro-collagen I N-propeptide (PINP) – than for bone-resorption markers (N-terminal and C-terminal telopeptide of type I collagen).

A 12% net reduction in bone ALP predicted a 33% reduction in vertebral fracture risk, and a 30% net reduction in bone ALP predicted a 65% reduction in fracture risk, the researchers report in the Journal of Bone and Mineral Research, online January 10.

Similarly, for PINP, a 22% net reduction predicted a 30% reduction in vertebral fracture risk, and a 50% net reduction predicted a 62% reduction in fracture risk.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In meta-regression analyses, changes in bone ALP and PINP significantly predicted vertebral-fracture risk, but none of the BTMs significantly predicted the risk of nonvertebral or hip fractures.

“Fracture-endpoint trials for osteoporosis treatments are large and expensive, so relatively few new agents are expected in the near future,” Dr. Bauer said. “Our data suggest short-term changes in several bone turnover markers predict subsequent vertebral fractures.”

“Pooling individual-level data from multiple trials sponsored by pharmaceutical companies is feasible and may help expedite the testing of effective osteoporosis treatments,” he added.

Senior author Dr. Richard Eastell from the University of Sheffield, UK, told Reuters Health by email, “Our hope is that when drugs are developed for use in osteoporosis the changes in the markers will help to identify the optimal dose and regimen. For clinical use, the results support the use of bone-turnover markers for monitoring osteoporosis therapy. The greater the change in bone-turnover marker, the greater the therapeutic benefit.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: anti-resorptive drug therapy, bone marker changes, fracture reduction, Fractures, Osteoporosis, osteoporosis treatments

You Might Also Like:
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
  • Bone Turnover Markers Show Link to Iliac Histomorphometry in Older Women
  • Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal
  • Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.